The plasma levels of a panel of cytokines and cytokineassociated molecules (IL-1␣, IL-2, IL-4, IL-6, IL-10, IL-12, IL-15, macrophage colony-stimulating factor (M-CSF), interferon-␥ (IFN-␥), tumor necrosis factor-␣ (TNF-␣), soluble IL-2 receptor (sIL-2R), soluble tumor necrosis factor receptor I or II (sTNFRI or II)) were assessed in 56 plasma samples of 13 pediatric patients undergoing hematopoietic stem cell transplantation (HSCT, bone marrow in 12 and cord blood in one) from unrelated donors. Eight patients developed severe (grade III-IV) acute GVHD (aGVHD). The plasma IL-6, IL-10, M-CSF, sTNFRI and II levels were significantly high in the severe aGVHD group compared to the mild aGVHD group (grade 0-II). The plasma IL-15 level increased transiently in the early period following HSCT and remained high in the severe aGVHD group even after 4 weeks following HSCT. Based on analysis of the correlations between the kinetics of the plasma cytokine levels after HSCT and the clinical manifestations of aGVHD, IL-15 and/or M-CSF were involved in the development of aGVHD, following elevation of the plasma IL-10 and sTNFRI or II levels. These kinetics suggest that IL-10 and sTNFRs worked as suppressor cytokines and seemed to suppress clinical manifestations of aGVHD. Furthermore, it seemed that the plasma ratio of IL-10/sTNFRII from 5 to 12 weeks following HSCT was linked to the poor outcome in the patients with severe aGVHD, suggesting that IL-10 plays an important role in protecting hosts from transplantation-related complications, including GVHD.
Hematopoietic stem cell transplantation (HSCT) is common in the pediatric population as treatment for leukemia, aplastic anemia, immunodeficiency and metabolic diseases. However, graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after HSCT, 1,2 especially when the graft is from unrelated donors or HLA-nonidentical family members. 3, 4 Because cytokines are important mediators, the modulation of different cytokines in the microenvironment may play an important role in determining the occurrence and severity of an immune response. It has been elucidated that many cytokines are involved in the development of GVHD following HSCT. 5, 6 Interleukin (IL)-1 involvement in GVHD has been implicated by Ferrara et al. [7] [8] [9] The administration of IL-1 receptor antagonist, a natural inhibitor of both IL-1␣ and IL-1␤, improved GVHD symptoms in a majority of patients, with few side-effects. 7, 10 Elevation of serum soluble IL-2 receptor (sIL-2R) has been found in GVHD, veno-occlusive disease and infection. 11, 12 IL-6 is also involved in the development of GVHD and infections following bone marrow transplantation (BMT). [13] [14] [15] Furthermore, tumor necrosis factor (TNF)-␣, interferon (IFN)-␥ and IL-15 were reported to be involved in the development of GVHD. [15] [16] [17] [18] [19] In contrast, within the cytokine network, activation of these proinflammatory mediators is followed by increased production of endogenous inhibitory molecules, including antagonistic cytokines. 20 Among them, IL-10 has raised substantial interest: IL-10 is produced by both monocytes/macrophages and T cells belonging to the Th0, Th1 and Th2 subsets. 21 IL-10 suppresses the production of proinflammatory monokines and modulates the expression of important costimulatory molecules such as CD80 on antigen-presenting cells. 22 Moreover, it inhibits alloantigen-induced T cell activation. 23 Based on the biological characteristics of IL-10, it has been suggested that IL-10 might be a suppressive mediator involved in preventing GVHD and inducing T cell tolerance in the setting of HSCT. To date, some reports have demonstrated an association of increased IL-10 levels with transplantation-related complications, including GVHD. [24] [25] [26] We performed a study on the plasma levels of a panel of cytokines and cytokine-associated molecules, such as sIL-2R and soluble TNF receptors (sTNFRs), in the setting Bone Marrow Transplantation of HSCT from unrelated donors in pediatric patients. We then discussed the correlations between the patterns of change in those plasma cytokine levels and the clinical manifestation of acute GVHD (aGVHD).
Materials and methods

Patients
Serial evaluations of the plasma cytokine levels were performed for 13 patients who underwent unrelated allogeneic HSCT at our center between July 1996 and April 1999 ( Table 1 ). The median age of the patients at HSCT was 8 years (range 1-13). Twelve patients received bone marrow and one received cord blood. The diagnoses included ALL (n = 5), AML (n = 3), CML (n = 3), JCML (n = 1) and AUL (n = 1). All patients received fractionated TBI (12 Gy) and various combinations of high-dose chemotherapy including melphalan (140-210 mg/m 2 ), cyclophosphamide (120 mg/kg), etoposide (60 mg/kg), cytarabine (12 g/m 2 ) and thiotepa (600 mg/m 2 ). For prophylaxis of graft-versushost disease (GVHD), tacrolimus and methylprednisolone (mPSL) were employed in the patients receiving HLAmatched unrelated bone marrows and a patient receiving two-loci-mismatched unrelated cord blood, and tacrolimus, methylprednisolone and short-course methotrexate (sMTX) in the patients receiving HLA one-locus-mismatched unrelated bone marrows. All patients were isolated in laminar air flow rooms and received oral non-absorbable antibiotics, oral acyclovir and amphotericin B syrup, and received G-CSF starting on day 5 after marrow or cord blood infusion.
The diagnosis of GVHD was made based on the histological findings of the specimens obtained by biopsy. Grading of aGVHD was performed according to the criteria described by Glucksberg et al. 27 Thrombotic microangiopathy (TMA) should be diagnosed by the histological findings, but the diagnosis of TMA was sometimes made clinically when accompanied by otherwise unexplainable laboratory findings such as a rapid decrease in the RBC count, detection of RBC fragmentation or an increase in LDH. One patient developed no signs of aGVHD, whereas grade II aGVHD was noted in three patients, grade III in four patients and grade IV in five patients (Table 1) . Two groups were established according to the grading of aGVHD: mild aGVHD (grades 0-II) and severe aGVHD (grades III-IV). The patients with aGVHD were treated with immunosuppressive agents such as high-dose mPSL, MTX, dexamethasone, azathioprine, anti-thymocyte globulin, VP-16 or thalidomide. Ten patients had an infection caused by a bacterium or fungus in the early period following HSCT, and one patient developed enterocolitis caused by cytomegalovirus (CMV). Four patients who were diagnosed as having TMA developed unexplained effusions as defined by Seber et al. 28 
Measurement of cytokines
We collected the patients' plasma before and every 2 weeks up to 12 weeks after HSCT and stored them at −80°C. ELISA was used to measure the plasma concentrations of interleukin-1␣ (IL-1␣; Otsuka Assay Laboratory, Tokyo, Japan), IL-2 (Otsuka Assay Laboratory), IL-4 (R&D Systems, Abingdon, UK), IL-6 (R&D System), IL-10 (Otsuka Assay Laboratory), IL-12 (R&D System), macrophage colony-stimulating factor (M-CSF; Otsuka Assay Laboratory), interferon-␥ (IFN-␥; Otsuka Assay Laboratory), TNF-␣ (Otsuka Assay Laboratory), soluble TNF receptor I (sTNFRI; Genzyme, Minneapolis, MN, USA), sTNFRII (Genzyme), and CLEIA for soluble IL-2 receptor (sIL-2R, EURO/DPC, Gwynedd, UK). All assays were performed according to the manufacturers' instructions at Otsuka Assay Laboratory (Tokyo, Japan). Detection limits were as follows: 3.4 pg/ml for IL-1␣, 20.0 pg/ml for IL-2 and M-CSF, 0.3 pg/ml for IL-4, 0.16 pg/ml for IL-6, 10.0 pg/ml for IL-10, 0.78 pg/ml for IL-12, 6.9 pg/ml for IFN-␥ and TNF-␣, 3.0 pg/ml for IL-15, 85.8 pg/ml for sTNFRI and sTNFRII and 50.0 U/ml for sIL-2R. Normal values of these cytokines and soluble receptors described here were obtained from healthy adult volunteers (Table 2 ). There were no significant differences between the patients' plasma levels of cytokines obtained pre-HSCT and the normal values. All values at pre-HSCT except those of IL-6 in UPN 147 and 174 and that of IL-15 in UPN 178 were within normal values. UPN 147 and 174 had viral infection at that time, which was the cause of high levels of plasma IL-6. It seemed that a high level of plasma IL-15 at pre-HSCT in UPN 178 was caused by the preconditioning regimens.
Statistical analysis
Statistical analysis was done using Student's t-test and Pearson's correlation coefficient. A level of P Ͻ 0.05 was considered statistically significant. Week 1 comprises day 1 to day 7, week 2 day 8 to 14, etc.
Results
We evaluated the plasma levels of IL-1␣ (n = 56), IL-2 (n = 56), IL-4 (n = 56), IL-6 (n = 56), IL-10 (n = 56), IL-12 (n = 51), M-CSF (n = 56), IFN-␥ (n = 56), TNF-␣ (n = 56), IL-15 (n = 54), sTNFRI (n = 56), sTNFRII (n = 56) and sIL-2R (n = 55). The plasma levels of IL-2, IL-4 and IL-12 in all samples tested were below the detection limits.
Comparison of post-HSCT cytokines and soluble receptors levels between mild and severe acute GVHD groups
A significant correlation was found between the severity of acute GVHD and the plasma levels of IL-6, IL-10, M-CSF, sTNFRI and sTNFRII ( Table 2 ). The kinetics of these cytokines and soluble receptors following HSCT are shown in Figure 1 . The plasma IL-15 level increased within 3 weeks following HSCT compared to the samples collected before HSCT in all patients except UPN 191 ( Figure 1 ). The IL-15 level decreased in the plasma samples obtained from the patients with mild aGVHD after 4 weeks, but in the samples from severe aGVHD it remained high even after 4 weeks following HSCT (Figure 1 ). Therefore, we assessed Significant differences between the severe GVHD III-IV () and the mild GVHD 0-II (í) groups, were evaluated as described in Materials and methods (* P Ͻ 0.05).
significant differences in the plasma IL-15 level separately from 0 to 3 weeks and after 4 weeks following HSCT ( No further significant correlations between the plasma levels of IL-1␣, IFN-␥, TNF-␣ and sIL-2R and the severity of acute GVHD were found. We detected a high plasma level of IL-1␣ following HSCT in only three samples. One of these samples was obtained from UPN 164 before BMT, which implied that the level of IL-1␣ was possibly associated with the progression of the disease because this patient relapsed just before BMT. The two other samples were obtained from patients with severe aGVHD after HSCT, but no clear correlation between the high level of IL-1␣ and the clinical findings was established. Whether the sIL-2R level after HSCT is a good indicator of aGVHD remains unclear. 11, 12, 29 In the present study, there was a tendency to significance between a high sIL-2R level and the severity of aGVHD, but statistical significance was not established because the plasma sIL-2R level was increased in the patients with an infection. TNF-␣ and IFN-␥ were thought to be an effector cytokine for the development of GVHD, but no definite peak of either cytokine could be found in plasma samples obtained after HSCT in our study.
Correlation of post-HSCT cytokines and soluble receptors levels with the clinical manifestation of acute GVHD
We then looked for correlations between the patterns of change in the cytokine levels and the clinical manifestation of aGVHD. First, we determined the kinetics of the IL-15 and M-CSF plasma levels after BMT in UPN 174 and compared them with the clinical manifestations ( Figure 2 ). Remarkably high levels of IL-15 and M-CSF were observed on day 6, and then a skin rash emerged on day 9. The plasma levels of IL-15 and M-CSF decreased rapidly in response to a high-dose of mPSL and then skin GVHD resolved. IL-15 and M-CSF increased again at 4 weeks following BMT, simultaneously with the onset of gut GVHD. In this patient, two definite peaks were observed for the plasma IL-15 and M-CSF levels, which coincided with exacerbation of the clinical manifestation of aGVHD. Similar kinetics for the IL-15 and M-CSF levels were also observed in UPN 173 (Figure 2) . Also, the plasma levels of IL-15 and M-CSF increased with the development of aGVHD symptoms in UPN 182 and UPN 191 (data not shown). The kinetics of the plasma IL-15 level paralleled those of M-CSF in the severe aGVHD group (r = 0.57546 Ͼ r 0.001 , n = 37). In the mild aGVHD group, the plasma IL-15 level increased transiently after HSCT, but no increase in the plasma M-CSF level was detected as shown in Figure 1 . At the time of the increase in the plasma IL-15 level, the patients exhibited a mild, transient skin rash.
Next, we investigated the kinetics of the IL-10 and sTNFRI or sTNFRII levels after HSCT. The kinetics of IL-10, sTNFRI and sTNFRII were associated with the clinical manifestation of aGVHD in the patients with severe aGVHD ( Figure 3 ) whereas significant increases in the plasma IL-10, sTNFRI or sTNFRII levels were never detected in the patients with mild aGVHD (Figure 1 ). The change in the plasma IL-10 level closely paralleled the change in the plasma sTNFR levels (IL-10 vs sTNFRI, r = 0.60145 Ͼ r 0.001 , n = 39; IL-10 vs sTNFRII, r = 0.77644 Ͼ r 0.001 , n = 39). Furthermore, we observed that the first peaks of IL-10, sTNFRI and sTNFRII were delayed relative to the first peaks of M-CSF and IL-15 in UPN 173 ( Figure  3a ) and 174 (Figure 3b ).
Unresponsive production of IL-10 in the severe aGVHD group
We found unresponsive production of plasma IL-10 from 5 to 12 weeks after HSCT compared to the increase in the plasma sTNFR levels in some patients showing severe aGVHD symptoms. We then looked for a correlation between the IL-10/sTNFRII ratio from 5 to 12 weeks after HSCT and the outcome in the severe aGVHD group. As shown in Figure 4 , patients with grade IV aGVHD and a patient with grade III who died of complications associated with acute GVHD showed low ratios of less than 13.6. In contrast, two of three patients with grade III acute GVHD Correlation between patterns of change in plasma M-CSF or IL-15 and IL-10, sTNFRI or sTNFRII. The plasma samples were collected before (pre) and after HSCT and measured the level of IL-10 (square, pg/ml), M-CSF (black bar, pg/ml), sTNFRI and II (rhomb, pg/ml) by an ELISA in UPN173 (a). The plasma samples were collected before (pre) and after HSCT and measured the level of IL-10 (square, pg/ml), IL-15 (black bar, pg/ml), sTNFRI and II (rhomb, pg/ml) by an ELISA in UPN174 (b). The clinical manifestation and stage (S) of acute GVHD is represented.
who showed a high ratio survived. UPN191 showed a high ratio (24.5), but died of TMA.
Discussion
It has been demonstrated that several cytokines play important roles in modulating immune responses following allogeneic HSCT. In this study, we documented significant peaks of plasma levels of IL-15 or M-CSF, both in some cases, following HSCT from unrelated donors and found that these peaks were closely associated with the development of aGVHD symptoms. These findings suggest that IL-15 and M-CSF may be involved in the development of aGVHD. Although the first peak of IL-15 in the plasma was similar in all patients as shown in Figure 1 , prolonged circulating IL-15 was demonstrated only in the patients with severe aGVHD, which is in accordance with the report by Kumaki et al. 18 Previous reports have suggested that IL-2 production following HSCT plays an important role in the development of acute GVHD. 30, 31 However, we could not detect significant production of IL-2 in any of the samples in this study. Similar results were also reported by Kumaki et al 18 and Imamura et al. 32 This can be explained by the dramatically decreased number of T cells, which are a rich source of IL-2, after pretransplant conditioning. Moreover, in human trials, neutralizing antibodies against IL-2 or the IL-2 receptor ␣ chain were unable to eliminate GVHD, 33, 34 suggesting that a cytokine other than IL-2 controls the effector cells. IL-15 which was significantly elevated in the severe aGVHD group, is one of the candidates for control of the effector cells because IL-15 has many overlapping biological activities with IL-2, such as costimulation of T cell proliferation and induction of cytotoxic activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. 35 IL-15 may be produced by tissue macrophages, epithelial cells, fibroblasts, keratinocytes and endothelial cells 18 even in the early phase of aGVHD. The first peak of IL-15 in the plasma observed during the early period of HSCT (0-3 weeks) may be caused by tissue damage following the preconditioning regimens or the response to alloantigens. Moreover, IL-15 may be important for engraftment because the increase in the white blood cell (WBC) count was followed by the first peak of IL-15. Sustained plasma IL-15 levels (4 weeks later) were observed only in the severe aGVHD group, and elevation of the IL-15 level was closely associated with the development of aGVHD symptoms, suggesting that the production of IL-15 after 4 weeks may be involved in the development of aGVHD symptoms. M-CSF is also known to be necessary for engraftment after HSCT or hematopoietic recovery after chemotherapy, 36, 37 and to stimulate monocytes/macrophages to produce various cytokines, such as IL-1, 38 TNF 39 and granulocyte colony-stimulating factor (G-CSF). 40 This cytokine network may be involved in the development of aGVHD. GVHD is initiated by the interaction of donor T cells with alloantigens on host tissues. However, during the early period post HSCT, nonspecific macrophage inflammatory mechanisms become activated because of the suppressed state of T and B cells. Indeed, a key step in the efferent phase of aGVHD is the progressive activation or priming of macrophages, [41] [42] [43] [44] suggesting that the increase in plasma M-CSF detected in the severe aGVHD group may be directly linked to activation of macrophages in the target organs. In the present study, a significant increase in the plasma M-CSF level which paralleled the increase in IL-15 was detected in the severe aGVHD group, whereas no significant increase in the plasma M-CSF levels was detected in the mild aGVHD group even from 0 to 3 weeks following HSCT, which raises an interesting suggestion about the mechanisms of aGVHD. After recognizing alloantigens, macrophages produce monocyte-derived cytokines (monokines), including IL-15, that bind to constitutively expressed monokine receptors on NK cells. Stimulated NK cells in turn produce cytokines that activate the macrophage, including IFN-␥ 45 and M-CSF. 46 Thus, an immune crosstalk between activated macrophages and NK cells may play a critical role in the development of aGVHD.
Increases in the plasma IL-10, sTNFRI and II levels were clearly associated with the development of aGVHD symptoms. Furthermore, based on the clinical findings in the patients with severe aGVHD shown in Figure 3 , the increases in plasma IL-10 and sTNFRI or II levels occurred after the peak in the plasma M-CSF and/or IL-15 levels. No significant increase in plasma IL-10 or the sTNFRs was detected in the mild aGVHD group. These findings suggest that plasma IL-10 and the sTNFRs may increase in response to the increase in IL-15 and/or M-CSF. IL-10 was initially described as a cytokine synthesis inhibitory factor, a product of Th2 clones, which inhibited Th1 cytokine production and function. 21 IL-10 is known to be produced by a variety of cells, including activated T cells, monocytes and B cells. 22 It strongly inhibits the antigen-specific proliferative response of T cells 23 and suppresses the production of various proinflammatory cytokines such as IL-1␣, IL-1␤, IL-6 and TNF-␣. [47] [48] [49] [50] Moreover, IL-10 was reported to stimulate sTNFRI production and inhibit monocyte chemoattractant protein-1 release from IL-1 beta-activated fibroblasts in vitro. 51 It was recently shown that IL-10 production after BMT might be useful for predicting the severity of GVHD, and high IL-10 production was associated with fewer transplant-related complications, including acute GVHD. [24] [25] [26] 52 In our present observations, the plasma sTNFRI or II levels followed a pattern similar to the plasma IL-10 level, which suggests that sTNFRI and II may work as antiinflammatory cytokines as well as IL-10 in the setting of aGVHD after HSCT. TNF-␣ is known to be an important mediator of tissue damage during GVHD. 16, 17 TNF-␣ binds to two receptors, p55 and p75, both of which are expressed on all hematopoietic cells with the exception of erythroid and unstimulated T cells. TNF-␣ can induce cytotoxicity, which is predominantly linked to the p55 receptor. TNF-␣ binding to the p75 receptor can enhance cytotoxicity through the p55 receptor by a process of ligand passing. In a well-characterized mouse model of GVHD, T cells from p55 receptor knock-out mice have a reduced capacity to induce GVHD, which indicates that TNF-␣/p55 receptor interactions are involved in the development of GVHD. 19 Chasty et al 53 reported that the sTNFR levels increased in association with transplant-related complications, including GVHD and infections. In our study, the plasma sTNFR levels were clearly associated with the signs of aGVHD, not infection, and this is the first report demonstrating that like IL-10, the plasma sTNFR levels after HSCT increase to suppress effector cytokines in the setting of aGVHD.
We demonstrated in this study that IL-10 production deteriorated around 5-12 weeks following HSCT compared to the plasma level of sTNFR in the patients with uncontrollable, severe aGVHD. This finding led us to surmise that the plasma IL-10/sTNFR ratio is a suitable marker for predicting the prognosis of severe aGVHD. The usefulness of the ratio may be limited to the severe aGVHD group because both IL-10 and sTNFRII fail to increase in the mild aGVHD group. Although further investigations will evaluate the true significance of this ratio, the patients showing a low ratio (under 20) developed grade IV acute GVHD or died of complications associated with severe aGVHD. The patients with uncontrollable, severe aGVHD (showing a low ratio of Ͻ20) had been serially administered various immunosuppressants, such as a high-dose of mPSL, ATG or tacrolimus, which may suppress the normal antiinflammatory response of IL-10.
Recently, researchers reported an imbalance of Th1 and Th2 helper T cells in GVHD. 54, 55 We also measured the plasma levels of such Th1 cytokines, IL-2, IL-12 and IFN-␥, but these cytokine levels were not associated with the severity of aGVHD.
Although our findings were not always consistent with those in the published literature, we could demonstrate a novel aspect of the mechanisms of aGVHD based on our present observations. IL-15 and M-CSF, the first cytokines to increase following HSCT, may work as effector cytokines of aGVHD, and IL-10 and sTNFR then increase in the plasma in response to the increase of IL-15 and M-CSF as suppressor cytokines. Evidence of the importance of producing the suppressor cytokines after HSCT raises the possibility that exogenous suppressor cytokines can be developed as a new strategy for managing GVHD.
